|
1
|
Huang Y, Ning Y, Chen Z, Song P, Tang H, Shi W, Wan Z, Huang G, Liu Q, Chen Y, Zhou Y, Li Y, Zhan Z, Ding J, Duan W, Xie H. A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease. Molecules 2024; 29:1803. [PMID: 38675622 PMCID: PMC11052001 DOI: 10.3390/molecules29081803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2024] [Revised: 04/10/2024] [Accepted: 04/12/2024] [Indexed: 04/28/2024] Open
Abstract
IRAK4 is a critical mediator in NF-κB-regulated inflammatory signaling and has emerged as a promising therapeutic target for the treatment of autoimmune diseases; however, none of its inhibitors have received FDA approval. In this study, we identified a novel small-molecule IRAK4 kinase inhibitor, DW18134, with an IC50 value of 11.2 nM. DW18134 dose-dependently inhibited the phosphorylation of IRAK4 and IKK in primary peritoneal macrophages and RAW264.7 cells, inhibiting the secretion of TNF-α and IL-6 in both cell lines. The in vivo study demonstrated the efficacy of DW18134, significantly attenuating behavioral scores in an LPS-induced peritonitis model. Mechanistically, DW18134 reduced serum TNF-α and IL-6 levels and attenuated inflammatory tissue injury. By directly blocking IRAK4 activation, DW18134 diminished liver macrophage infiltration and the expression of related inflammatory cytokines in peritonitis mice. Additionally, in the DSS-induced colitis model, DW18134 significantly reduced the disease activity index (DAI) and normalized food and water intake and body weight. Furthermore, DW18134 restored intestinal damage and reduced inflammatory cytokine expression in mice by blocking the IRAK4 signaling pathway. Notably, DW18134 protected DSS-threatened intestinal barrier function by upregulating tight junction gene expression. In conclusion, our findings reported a novel IRAK4 inhibitor, DW18134, as a promising candidate for treating inflammatory diseases, including peritonitis and IBD.
Collapse
Affiliation(s)
- Yuqing Huang
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
- College of Pharmacy, Guizhou Medical University, Guiyang 561113, China
| | - Yi Ning
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
- University of Chinese Academy of Sciences, Beijing 100049, China;
| | - Zhiwei Chen
- University of Chinese Academy of Sciences, Beijing 100049, China;
- Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.C.); (Z.Z.)
| | - Peiran Song
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
| | - Haotian Tang
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
| | - Wenhao Shi
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
| | - Zhipeng Wan
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
| | - Gege Huang
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
| | - Qiupei Liu
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
- Department of Chemical and Environment Engineering, Science and Engineering Building, The University of Nottingham Ningbo China, Ningbo 315100, China
| | - Yun Chen
- Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.C.); (Z.Z.)
| | - Yu Zhou
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
| | - Yuantong Li
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
| | - Zhengsheng Zhan
- Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.C.); (Z.Z.)
| | - Jian Ding
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
| | - Wenhu Duan
- University of Chinese Academy of Sciences, Beijing 100049, China;
- Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.C.); (Z.Z.)
| | - Hua Xie
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; (Y.H.); (P.S.); (H.T.); (W.S.); (Z.W.); (G.H.); (Y.Z.); (Y.L.)
- College of Pharmacy, Guizhou Medical University, Guiyang 561113, China
- Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; (Y.N.); (Q.L.); (J.D.)
- University of Chinese Academy of Sciences, Beijing 100049, China;
| |
Collapse
|
|
2
|
Bilyayeva O, Kryzhevsky V, Karol I, Ziablitzev S. The association of TLR4 gene polymorphisms with the severity of peritonitis in acute inflammatory diseases of the abdominal cavity organs. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2024; 77:35-41. [PMID: 38431805 DOI: 10.36740/wlek202401105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
OBJECTIVE Aim: To determine the role of TLR4 gene polymorphisms as risk factors for peritonitis severity in patients undergoing surgery for acute inflammatory diseases of the abdominal cavity. PATIENTS AND METHODS Materials and Methods: The study included 139 patients who were operated on for acute abdominal diseases (acute appendicitis and cholecystitis, perforated gastric or duodenal ulcer, etc.). Depending on the number of points on the modified APACHE II scale, patients were divided into two groups: Group 1 - 1-3 points (63 patients, 45.3%) and Group 2 - 4 or more points (76 patients, 54.7%). Polymorphisms rs1927911, rs2149356 and rs4986790 were determined by polymerase chain reaction. RESULTS Results: The rs1927911 polymorphism of the TLR4 gene was protective for the development of peritonitis (according to the allelic model, OR 0.48; 95% CI 0.27-0.84; p=0.015). Regression analysis revealed a reduced (p=0.015) risk of severe peritonitis in rs1927911 A/A or G/A genotype carriers (OR 0.42; 95% CI 0.21-0.84) compared with G/G genotype carriers. There was no effect on the severity of peritonitis of TLR4 polymorphisms rs2149356 and rs4986790. There was a tendency to increase the frequency of the mutant G rs4986790 allele in patients with severe peritonitis (χ2=2.17; p<0.001). The analysis of the association of TLR4 gene polymorphisms with the phenotype of patients showed that carriers of mutant homozygotes and heterozygotes in the presence of severe peritonitis were older, had a tendency to coagulopathy, higher leukocytosis and leukocyte clotting rate. CONCLUSION Conclusions: Thus, the importance of TLR in the development of severe peritonitis was confirmed and the protective role of the rs1927911 promoter polymorphism was established.
Collapse
Affiliation(s)
- Olga Bilyayeva
- SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE
| | | | - Ivan Karol
- SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE
| | | |
Collapse
|
|
3
|
Chen Y, Chen X, Qian H, Li B, Su X. Acupuncture alleviates acute peritonitis: A case report. Heliyon 2023; 9:e15290. [PMID: 37095912 PMCID: PMC10121459 DOI: 10.1016/j.heliyon.2023.e15290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 03/28/2023] [Accepted: 03/31/2023] [Indexed: 04/08/2023] Open
Abstract
Many inflammatory and infectious entities can affect the peritoneum acutely, and patients with peritonitis often have painful expressions. Abdominal pain can be aggravated by coughing, breathing, and turning the body. Here we report the case of an 88-year-old patient with acute gastrointestinal perforation. The patient has been experiencing pain in the right lower abdomen, presenting persistent colic. The X-ray of abdomen and abdominal computed tomography showed perforation of digestive tract. In addition to the use of anti-infection and stomach protection agents, we use different analgesic injections, but the effect on reducing the pain was not obvious. After acupuncture treatment, the patient quickly relieved the pain of acute peritonitis in 1 minute. However, to our knowledge, there is few literature showing that acupuncture relieves preoperative opioid-induced hyperalgesia in patients with acute peritonitis. Based on this case, we suggest acupuncture as an option in the management of relieving the pain of acute peritonitis when opioid therapy is ineffective.
Collapse
Affiliation(s)
- Yun Chen
- Guangdong Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, Foshan, PR China
| | - Xiaoyan Chen
- The Fifth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, PR China
| | - Hong Qian
- Guangdong Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, Foshan, PR China
| | - Biyi Li
- Foshan Traditional Chinese Medicine Hospital, Foshan, PR China
| | - Xuan Su
- The Ninth People's Hospital of Nanhai District, Foshan, PR China
- Corresponding author.
| |
Collapse
|
|
4
|
Watanabe Y, Yamazaki S, Yokoyama H, Yakubo S, Osaki A, Takaku K, Sato M, Waguri N, Terai S. A Rare Case of Recurrent Generalized Peritonitis Caused by Spontaneous Urinary Bladder Rupture after Radiotherapy: A Case Report and Literature Review. MEDICINES 2021; 8:medicines8110067. [PMID: 34822364 PMCID: PMC8617802 DOI: 10.3390/medicines8110067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Revised: 10/27/2021] [Accepted: 11/02/2021] [Indexed: 11/16/2022]
Abstract
Since generalized peritonitis is a fatal disease, accurate diagnosis and treatment are important. In this paper, we report a case of recurrent generalized peritonitis associated with spontaneous urinary bladder rupture (SBR). A 65 year old woman, who underwent radiotherapy 21 years prior, was diagnosed with generalized peritonitis. Although the cause of the generalized peritonitis could not be identified, the patient recovered with conservative treatment in short period. However, recurrent episodes of generalized peritonitis occurred four times. We diagnosed the patient with urinary ascites due to SBR, based on a history of radiotherapy and dysuria. No recurrence of generalized peritonitis had occurred after accurate diagnosis and treatment with long-term bladder catheter placement. Since SBR often occurs as a late complication after radiotherapy, it is difficult to diagnose SBR, which leads to delayed treatment. This case and literature review of similar cases suggest that the information of the following might be helpful in the diagnosis of SBR: (i) history of recurrent generalized peritonitis, (ii) pseudo-renal failure, (iii) history of radiotherapy, (iv) dysuria, and (v) increase or decrease of ascites in a short period. It is important to list SBR in the differential diagnosis by knowing the disease and understanding its clinical features. This case and literature review will serve as a reference for future practices.
Collapse
Affiliation(s)
- Yusuke Watanabe
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
- Division of Preemptive Medicine for Digestive Disease and Healthy Active Life, School of Medicine, Niigata University, Niigata 951-8510, Japan
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan;
- Correspondence: ; Tel.: +81-25-227-2207; Fax: +81-25-227-0776
| | - Shun Yamazaki
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan;
| | - Hanako Yokoyama
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan;
| | - Shunta Yakubo
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan;
| | - Akihiko Osaki
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
| | - Kenichi Takaku
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
| | - Munehiro Sato
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
| | - Nobuo Waguri
- Department of Gastroenterology and Hepatology, Niigata City General Hospital, Niigata 950-1141, Japan; (S.Y.); (H.Y.); (S.Y.); (A.O.); (K.T.); (M.S.); (N.W.)
| | - Shuji Terai
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan;
| |
Collapse
|